MediGene AG · LS:A40ESG
MediGene — 9M 2011 Earnings Presentation
18 slides from MediGene's earnings presentation, Nov 11, 2011
Slide 1: Analyst Conference Call Financial Results 9 Months 2011
Analyst Conference Call Financial Results 9 Months 2011 November 11, 2011 Dr. Frank Mathias, Chief Executive Officer Arnd Christ, Chief Financial Officer
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: MediGene delivers
MediGene delivers
Slide 4: MediGene progresses in line with objectives
MediGene progresses in line with objectives Positive net result 9M 2011 contributes to solid financial situation Veregen®: • In-market sales growing continuously • New partnership agreements executed • Spain marketing authorization and pricing approval granted, preparations for market launch in
Slide 5: MediGene progresses in line with objectives
MediGene progresses in line with objectives RhuDex®: • New formulation strategy developed, customized for chronic treatment, which will be further tested and optimized in a formulation study • MHRA approval allows for resumption of clinical development EndoTAG®-1: • Final overall survival data f
Slide 6: EndoTAG-1 to be tested in new indication
EndoTAG®-1 to be tested in new indication Investigator initiated trial (IIT) of EndoTAG®-1 in combination with paclitaxel for hormone-receptor-positive, HER2-negative breast cancer. Prof. Dr. Ahmed Awada* will conduct „An open-label phase II trial evaluating the efficacy and safety of neoadjuvan
Slide 7: Strong financials in line with guidance
Strong financials in line with guidance
Slide 8: Positive result 9M 2011
Positive result 9M 2011 Veregen® revenue from product sales and royalties increased by 38% to €1.2 million 2% royalty on Eligard® net sales* totals €1.5 million Total revenue (from continued and discontinued operations): €30.7 million (including revenue from milestone payments of €20 million f
Slide 9: Veregen revenue increased continuously
Veregen® revenue increased continuously In € million Veregen® in-market sales Veregen in-market sales increased by 55%* 55 % (9M 2010 vs. 9M 2011) Veregen product sales and royalties increased by 38%* 25% 25% from €0.9 million (9M 2010) to €1.2 million (9M 2011) 9M 2010 9M 2011 *Increase not in
Slide 10: MediGene participates in Eligard revenue growth
MediGene participates in Eligard® revenue growth In € million Eligard in-market sales In-market sales increased by 7% 7% Since March 1, 2011 2% royalty on net sales Revenue from discontinued operations includes Eligard® milestones of €20 million from 9M 2010 9M 2011 Astellas 10
Slide 11: R&D and SG&A costs adapted to business needs
R&D and SG&A costs adapted to business needs In € million Research and development expenses Lower R&D and SG&A expenses -53% through 11.2 • Reduced personnel expenses 5.2 following the restructuring in 2010 9M 2010 9M 2011 • Successful completion of shift in EndoTAG®-1 CMC process Selling, general
Slide 12: Business performance leads to positive results
Business performance leads to positive results In € million EBITDA Positive EBITDA and net result Impact of strategic measures taken 14.5 in 2010 -9.6 • One-time milestone payments from transfer of Eligard rights led to 9M 2010 9M 2011 high revenues Net result for the period • Cost savings meas
Slide 13: Cash boosted by Eligard and financial asset sale
Cash boosted by Eligard and financial asset sale In € million 0 -0.3 1.5 9.4 15.4 4.8 Cash balance Cash flow Cash flow Cash flow Foreign Cash balance Jan. 1,2011 from operating from investing from financing exchange Sept. 30, 2011 activities activities activities differences Operating cash flow i
Slide 14: Outlook
Outlook
Slide 15: Financial outlook 2011 confirmed and updated
Financial outlook 2011 confirmed and updated Initial guidance included a €5 million milestone payment from Astellas, which was expected for end of 2011 or beginning of 2012 Milestone payment depends on transfer of Eligard®-rights for non-EU countries, which is now expected to happen in 2012 Fi
Slide 16: On track to continue delivering through 2012
On track to continue delivering through 2012 Veregen® • Market approvals and launches in additional countries • Submission of additional market approval applications • Additional marketing partnership agreements EndoTAG®-1 • Achieve global or regional licenses for the continued development of En
Slide 17: Q&A
Q&A Frank Mathias, CEO & Arnd Christ, CFO
Slide 18: MediGene AG contact details
MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com